Vera Therapeutics director Enright buys shares worth $5.2m

Director Patrick G. Enright of Vera Therapeutics , Inc. (NASDAQ:VERA) recently purchased shares of Class A Common Stock. On June 23 and 24, 2025, Enright acquired a total of 250,690 shares at prices ranging from $20.8683 to $22.3517, resulting in a total transaction value of $5,277,311. The stock, currently trading at $23.32, has shown strong momentum with an 11.42% gain over the past week. InvestingPro analysis reveals 10+ additional insights about VERA’s financial health and market position.

Specifically, on June 23, Enright purchased 69,798 shares and 139,595 shares. On June 24, the director then acquired another 13,536 shares and 27,071 shares. These shares are indirectly held by Longitude Prime Fund, L.P. and Longitude Venture Partners IV, L.P. Following these transactions, the total shares owned indirectly increased to 1,797,619 and 3,596,593 respectively. With a market capitalization of $1.47 billion and strong liquidity metrics, InvestingPro data shows analyst price targets ranging from $23 to $100 per share.

In other recent news, Vera Therapeutics has reported significant developments regarding its Phase 3 ORIGIN study of atacicept for treating immunoglobulin A nephropathy (IgAN). The study demonstrated a 42% placebo-adjusted reduction in urine protein creatinine ratio (UPCR) at Week 36, surpassing expectations and aligning with previous Phase 2b outcomes. Analysts at H.C. Wainwright responded by raising Vera’s stock price target to $85, emphasizing the strong data and potential for accelerated FDA approval. TD Cowen also maintained a Buy rating with a $60 price target, noting that the results exceeded both investor and firm expectations. JPMorgan reiterated an Overweight rating, maintaining a $68 price target, and highlighted the clean safety profile of atacicept. Evercore ISI maintained an Outperform rating with a $75 price target, expressing optimism about Vera’s upcoming FDA meeting for accelerated approval. These ratings reflect a broad consensus among analysts about the promising potential of atacicept in the competitive IgAN treatment market. Vera plans to file a Biologics License Application in late 2025, with a potential market launch in 2026.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.